The Division of Genitourinary Pathology consists of Dr. Debra Zynger (director), Dr. Larry DeRenne, Dr. Anil Parwani and Dr. Gary Tozbikian.
The division is responsible for an annual volume of 3600 cases with 73% in-house, non-consult cases. In-house, non-consult cases consist of a wide diversity and large oncologic volume including 300 nephrectomy, 250 robotic prostatectomy, 100 cystectomy, 50 adrenalectomy, 50 orchiectomy and 10 penectomy resections per year. Cases are complex and advanced tumors are not infrequent. For example, 45% of robotic prostatectomies are classified as pT3 and 60% of prostate biopsies performed have a diagnosis of carcinoma rendered.
Diagnostic immunohistochemical tests that have been implemented in the past decade by the Division of Genitourinary Pathology include laminin, CAIX, AR, OCT3/4, CD44s, GATA3, PAX8, NKX3.1, p40, SALL4, TFE3, SDHB, FH, CK5/p53 double stain, CK5/CK7 double stain and an inhouse cocktail of AMACR/p63/CK5. Diagnostic florescence in situ hybridization tests that have been implemented in the past decade include analysis of 3p/3q ratio for the work up of clear cell renal cell carcinoma.
The Division of Genitourinary Pathology participates in several monthly interdisciplinary meetings attended by Pathology, Urology, Genitourinary Oncology and Radiation Oncology including Urologic Oncology Tumor Board and Genitourinary Oncology Clinical Trial Update.
Subspecialty sign-out allows for in-depth teaching opportunities. Trainees specializing in Pathology or related disciplines such as Urology can take a 1 month resident or medical student rotation in Genitourinary Surgical Pathology. The division also participates in the required 3rd year medical student Surgical Pathology clerkship experience and the 2nd year medical student Career Exploration.
The Genitourinary Pathology division is actively involved in research projects and frequently collaborates with members of the departments of Urology, Oncology, Radiology and Radiation Oncology.